Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to improve research into acute myeloid leukaemia.

The Department is proud to invest £1.3 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, and more is spent on cancer than any other disease group.

The Government, through the NIHR, is committed to improving research into the cancers with the poorest survival rates, such as acute myeloid leukaemia, by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer, and other less survivable cancers. The following table shows NIHR research spend on diagnosis, treatment, and diagnosis and treatment of blood cancers, which includes leukaemia, since 2018:

In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council’s two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.

The NIHR continues to encourage and welcome applications for research into any aspect of human health, including acute myeloid leukaemia. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals, and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers, made through open competition, have been funded.